On March 22, 2011 the U.S. Supreme Court handed down a decision which is likely to have serious repercussions for companies in the bio/pharma tech space. In MATRIXX INITIATIVES, INC., ET AL. v. SIRACUSANO ET AL., the Court rejected Matrixx argument that reports regarding the adverse effect of Zicam, its leading revenue generating product, were not statistically significant and therefore not material.
Noting that the analysis of materiality under the securities laws in fact specific, the Court appears to have relied heavily on two factors:
1. The methodologies and requirements ...
Blog Editors
Recent Updates
- SEC Issues New Guidance Under Rule 701 for Employee Equity Compensation
- Video: NLRB and DOL Take Action on Joint Employer and Independent Contractor Rules - Employment Law This Week
- Massachusetts Court Rejects Individual Liability and Aiding-and-Abetting Claims Under Paid Family and Medical Leave Law
- Video: NYC Enforcement Blitz, CA Surveillance Pricing, and PA Criminal History Rule Update - Employment Law This Week
- EEOC Sends Warning to Fortune 500: What Employers Should Know